ReviewOvercoming remyelination failure in multiple sclerosis and other myelin disorders
Introduction
When the first pathological descriptions of multiple sclerosis (MS) were made at the end of the 19th century and the beginning of the 20th century two cardinal features of the disease were identified: first, acute inflammation associated with primary demyelination and second, axonal dystrophy and loss. The intervening decades have seen a considerable investment into the immunological aspects of the disease, reflected in the identification of several immune-related genes as genetic determinants of disease susceptibility (Oksenberg, et al., 2008) and an understanding of the disease pathogenesis that has translated into the development of highly effective immunomodulatory therapies (Coles et al., 2008, Compston and Coles, 2008).
Paradoxically, the success of this line of MS research has thrown into relief deficiencies in our understanding of aspects of the disease not directly related to immunology but that instead relate to neurobiology and in particular the interdependency between the axon and oligodendrocyte (Nave and Trapp, 2008). Thus, while immunomodulatory therapies are proving increasingly effective in controlling the initial relapsing-remitting phase of MS, the secondary progressive phase, in which there is a continual atrophy of demyelinated axons, remains untreatable. This occurs despite immunomodulatory therapies suggesting a mechanism independent of inflammation (Coles et al., 1999, Dutta and Trapp, 2007). Several lines of evidence suggest that the basis of axon atrophy in chronically demyelinated lesions is due, in part, to the absence of myelin-associated trophic signals that are critical for maintaining axon integrity. For example, oligodendrocyte-specific deletions in myelin associated genes PLP, MAG and CNPase do not cause any obvious defect in myelination, but eventually leads to axonal pathology (Griffiths et al., 1998, Lappe-Siefke et al., 2003, Li et al., 1994). Similarly, the substitution of PLP with the peripheral myelin protein P0 in mice leads to axonal dystrophy, implying an as yet uncharacterized trophic role for PLP in axonal maintenance (Yin et al., 2006).
These observations imply that an effective means of preventing axonal loss might be more efficacious myelin restoration. This process, called remyelination or, less accurately, myelin repair, can occur as a spontaneous regenerative process following demyelination (Duncan et al., 2009, Franklin and Ffrench-Constant, 2008). Indeed, remyelination is the default response to demyelination occurring with great efficiency in not only experimental models of demyelination but also following demyelination associated with traumatic injury and in many MS lesions, especially those occurring early in the disease (Blakemore, 1973, Lasiene et al., 2008, Patani et al., 2007, Patrikios et al., 2006). Nevertheless, it is clear that in MS remyelination frequently fails leading to persistent demyelination and eventually axon degeneration (Patrikios et al., 2006). In this respect, there may be lessons learned from MS that can apply to other conditions. Periventricular leukomalacia (PVL), which primarily affects the brain of premature infants and can lead to cerebral palsy, also demonstrates failure of myelin repair (Billiards et al., 2008), which might result from and/or play a role in the subsequent development of axonal degeneration (Haynes et al., 2008).
How, therefore, might remyelination in MS and possibly other human myelin disorders be enhanced? One proposed approach that has attracted considerable attention is to bypass the endogenous process and transplant myelinogenic cells of which several types have been described. However, this approach presents a variety of obstacles, including how to achieve (1) the proper delivery and distribution of cells within a multifocal disease, (2) efficiency of repair within demyelinated environments that–as indicated above–do not support endogenous repair, and (3) generation of large numbers of cells that may require immunosuppressive protocols. For these and other reasons (reviewed previously (by Baron-Van Evercooren et al., 2004, Franklin and Ffrench-Constant, 2008) this strategy will not be further addressed here. An alternative approach is to identify ways of enhancing the endogenous remyelination process based on a precise and comprehensive knowledge of why remyelination fails.
The principal source of new remyelinating cells is an abundant and widespread population of cells in the adult CNS traditionally called oligodendrocyte precursor cells (OPCs). These cells are both self-renewing in the adult and can give rise to certain neurons in vivo, and so could reasonably be regarded as type of adult neural stem cell (however, changes in nomenclature often lag behind experimental evidence supporting these changes) (Nunes et al., 2003, Rivers et al., 2008, Zhu et al., 2008). For the purposes of this review we will use the term OPC to include NG2 cells. The innate immune response to demyelination causes OPCs to become activated, a morphological change accompanied by upregulation of genes not normally expressed in the resting state (Fancy et al., 2004, Glezer et al., 2006, Watanabe et al., 2004, Zhao et al., 2009). Activated OPCs divide and migrate and rapidly fill up the demyelinated lesions at a density that far exceeds that in normal tissue. To complete the remyelination process the cell must exit the cell cycle and differentiate into myelin sheath-forming oligodendrocytes, a complex process involving axon engagement, ensheathment and formation of compacted myelin (Chen et al., 2009, Crockett et al., 2005). As with all regenerative processes the efficiency of remyelination decreases with age, primarily due to a decrease in the ability of recruited cells to differentiate (Shields et al., 1999, Sim et al., 2002, Woodruff et al., 2004). This age-associated decline in remyelination mirrors and may be in part a determinant of a now well-recognised feature of many chronically demyelinated MS lesions that are replete with oligodendrocyte lineage cells that fail to differentiate into myelinating oligodendrocytes (Chang et al., 2002, Kuhlmann et al., 2008, Wolswijk, 1998).
Taken together both experimental and clinical-pathological studies point to the impairment of precursor differentiation as a key feature of inefficient or failed remyelination in MS. This means that identifying pathways involved in the regulation of OPC differentiation in myelination and especially remyelination that can potentially be manipulated pharmacologically represents a critical task in the development of new therapies for enhancing endogenous remyelination and thus axonal protection in MS and other myelin disorders. In this article we will review recent developments in the cell biology of precursor differentiation during remyelination and indicate how this knowledge may be translated into new drug-based therapies to overcome remyelination failure in MS and other myelin disorders. We focus on three signaling pathways—notch pathway (canonical and non-canonical), wnt pathway and pathways activated by myelin debris. Lingo-1 has also been implicated as a negative regulator of myelination (Mi et al., 2005) and, on the basis of pro-remyelination effects of Lingo-1 blocking antibodies, of remyelination (Mi et al., 2009). Since the therapeutic opportunities presented by Lingo-1 have been reviewed elsewhere (Rudick et al., 2008) we have not included a discussion of this topic in this review.
Section snippets
Regulators of differentiation I—the notch pathway
Whilst it is implicit that mitogens for OPCs, such as PDGF, are de facto inhibitors of differentiation, amongst the first pathways involved in regulating OPC differentiation per se was the Delta/Jagged-Notch pathway (Genoud et al., 2002, Wang et al., 1998). During development, activation of Notch receptors on OPCs by the Notch ligand, expressed from axons was shown to have an inhibitory regulatory effect on differentiation. This observation led to speculation that persistent signaling via the
Regulators of differentiation II—Wnt signaling
Transcription factors (TFs) as key components of regulatory pathways have attracted considerable attention in the biology of oligodendrogliogenesis and developmental myelination (Emery et al., 2009, He et al., 2007, Rowitch, 2004). The transcription factor Olig1, for example, appears to have critical roles in early OPC development (Xin et al., 2005) as well as remyelination (Arnett et al., 2004). A recent study by the authors set itself the task of performing a genome-wide screen of TFs
Regulators of differentiation III—myelin debris
The process of primary demyelination generates vast amounts of myelin debris as the compacted myelin unravels and is removed from axons. Several lines of evidence reveal the importance of phagocytic removal of myelin debris for efficient remyelination. First, histopathological observations of experimental demyelination have shown an association between efficiency of myelin debris removal and remyelination. The rapid and complete remyelination that occurs in young animals is associated with
Conclusions and future prospects
It is now widely acknowledged that inducing differentiation of oligodendrocyte lineage cells present within areas of demyelination into remyelinating oligodendrocytes represents a major focus of therapeutic remyelination research. Potentially this could be achieved either by overcoming putative inhibitors of differentiation present within lesions or by the administration of agents that induce differentiation. Critical to achieving this objective is the identification of pathways by which
References (70)
- et al.
Remyelination of the superior cerebellar peduncle in the mouse following demyelination induced by feeding cuprizone
J. Neurol. Sci.
(1973)- et al.
Multiple sclerosis
Lancet
(2008) - et al.
Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination
Cell
(2009) - et al.
Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS
Mol. Cell. Neurosci.
(2004) - et al.
The transcription factor yin yang 1 is essential for oligodendrocyte progenitor differentiation
Neuron
(2007) - et al.
F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation
Cell
(2003) - et al.
Contact with central nervous system myelin inhibits oligodendrocyte progenitor maturation
Dev. Biol.
(1999) - et al.
Epigenetic memory loss in aging oligodendrocytes in the corpus callosum
Neurobiol. Aging
(2008) - et al.
The Wnt/beta-catenin signaling pathway as a target in drug discovery
J. Pharmacol. Sci.
(2007)
Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease
Trends Mol. Med.
Notch receptor activation inhibits oligodendrocyte differentiation
Neuron
Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination
Mol. Cell. Neurosci.
Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination
Neurobiol. Aging
The bHLH transcription factor Olig1 is required for repair of demyelinated lesions in the CNS
Science
Myelin-mediated inhibition of oligodendrocyte precursor differentiation can be overcome by pharmacological modulation of Fyn-RhoA and protein kinase C signalling
Brain
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
Hum. Mol. Genet.
Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia
Brain Pathol.
Notch is tops in the developing brain
Curr. Biol.
Relationship between cell cycle molecules and the onset of oligodendrocyte differentiation
J. Neurosci. Res.
Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis
N. Engl. J. Med.
The oligodendrocyte-specific G protein-coupled receptor GPR17 is a cell-intrinsic timer of myelination
Nat. Neurosci.
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
N. Engl. J. Med.
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
Ann. Neurol.
Number of oligodendrocyte progenitors recruited to the lesioned spinal cord is modulated by the levels of the cell cycle regulatory protein p27Kip-1
Glia
Extensive remyelination of the CNS leads to functional recovery
Proc. Natl. Acad. Sci. U. S. A.
Pathogenesis of axonal and neuronal damage in multiple sclerosis
Neurology
Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS
Genes Dev.
Why does remyelination fail in multiple sclerosis
Nat. Rev. Neurosci.
Remyelination in the CNS: from biology to therapy
Nat. Rev. Neurosci.
Endothelin-1 regulates oligodendrocyte development
J. Neurosci.
Notch1 control of oligodendrocyte differentiation in the spinal cord
J. Cell Biol.
Failure of remyelination in areas of demyelination produced in the spinal cord of old rats
Neuropathol. Appl. Neurobiol.
Innate immunity triggers oligodendrocyte progenitor reactivity and confines damages to brain injuries
FASEB J.
Axonal swellings and degeneration in mice lacking the major proteolipid of myelin
Science
Cited by (154)
MedXercise: a promising strategy to promote remyelination
2021, Current Opinion in PharmacologyModulation of lanosterol synthase drives 24,25-epoxysterol synthesis and oligodendrocyte formation
2021, Cell Chemical BiologyDiscovery and Optimization of Selective Brain-Penetrant EBP Inhibitors that Enhance Oligodendrocyte Formation
2024, Journal of Medicinal ChemistryExtracellular vesicle-associated cholesterol supports the regenerative functions of macrophages in the brain
2023, Journal of Extracellular Vesicles